SHEN Xiaofang, LI Hong, WANG Chengxi. Two Proved Cases of Professor Wang Chengxi in the Treatment of Mycoplasma Pneumoniae Pneumonia[DB/OL].(2023-09-15)[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails#10.3969/j.issn.1003-8914.2021.11.020
SHEN Xiaofang, LI Hong, WANG Chengxi. Two Proved Cases of Professor Wang Chengxi in the Treatment of Mycoplasma Pneumoniae Pneumonia[DB/OL].(2023-09-15)[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails#10.3969/j.issn.1003-8914.2021.11.020DOI:
Mycoplasma pneumoniae pneumonia is one of the common community acquired pneumonia. Its incidence rate and recurrence rate increase with the increase of its resistance rate to the first choice. Professor Wang Chengxi believes that the disease is mostly caused by exogenous pathogens attacking the lung, entering the interior to turn heat, burning the lung gold, resulting in obstruction of the lung collaterals, phlegm heat and blood stasis being closed inside. The treatment is mainly Zhiyan mixture, combined with syndrome differentiation treatment, playing the function of clearing heat, resolving phlegm and detoxification, promoting lung opening, closing and unblocking collaterals.
关键词
肺炎支原体肺炎中医药疗法王诚喜医案咳喘
Keywords
mycoplasma pneumoniae pneumoniatherapy of traditional Chinese medicineWang Chengxiconsiliacough with dyspnea
references
MEDJO B, ATANASKOVIC-MARKOVIC M, RADIC S, et al. Mycoplasma pneumoniae as a causative agent of community acquired pneumonia in children: clinical features and laboratory diagnosis[J]. Ital J Pediatr, 2014, 40: 104.
DEANTONIO R, YARZABAL J, CRUZ J P, et al. Epidemiology of community acquired-pneumonia and implications for vaccination of children living in developing and newly industrialized countries: A systematic literature review[J]. Hum Vaccin Immunother, 2016, 12(9): 2422-2440.
FAN Q, MENG J, LI P J, et al. Pathogenesis and association of Mycoplasma pneumoniae infection with cardiac and hepatic damage[J]. Microbiol Immunol, 2015, 59(7): 375-380.
YANG T I, CHANG T H, LU C, Y, et al. Mycoplasma pneumoniae in pediatric patients: Do macrolide-resistance and/or delayed treatment matter? [J]. J Microbiol Immunol Infect, 2019, 52: 329-335.